Sex steroids in autoimmune diseases

Current Topics in Medicinal Chemistry

Volumn 11, Issue 13, 2011, Pages 1668-1683

  Martocchia, A ^a   Stefanelli, M ^a   Cola, S ^a   Falaschi, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoimmune disease; Sex steroid; Sex steroid receptor

Indexed keywords

17 ALPHA ETHYNYL 5 ANDROSTENE 3BETA, 7BETA, 17BETA TRIOL; 5 ALPHA DIHYDROTESTOSTERONE; 5 ANDROSTENE 3BETA, 7BETA, 17BETA TRIOL; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIOL; CLOMIFENE; CYTOKINE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUASTERONE; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; HE 2200; HE 3286; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NOMEGESTROL ACETATE; PRASTERONE; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TIBOLONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANDROGEN DEFICIENCY; ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW CELL; CALCIUM TRANSPORT; CAVEOLA; CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLLAGEN INDUCED ARTHRITIS; DISEASE COURSE; DISEASE SEVERITY; DNA BINDING; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENCEPHALOMYELITIS; ENDOPLASMIC RETICULUM; ENDOTHELIUM; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN RESPONSIVE ELEMENT; FLOW CYTOMETRY; GENDER; GENE; GENE EXPRESSION; HORMONE ACTION; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HYPERANDROGENISM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INCIDENCE; KLINEFELTER SYNDROME; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; MACROPHAGE; MENOPAUSE; META ANALYSIS (TOPIC); METABOLITE; MITOCHONDRION; MORTALITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PHAGOCYTOSIS; PLACENTA; PREGNANCY; PREVALENCE; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RECEPTOR GENE; REGULATORY T LYMPHOCYTE; RELAPSE; RHEUMATOID ARTHRITIS; SEXUAL FUNCTION; SIALOADENITIS; SIGNAL TRANSDUCTION; STEROID METABOLISM; STROMA CELL; SYNOVIAL FLUID; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; T LYMPHOCYTE; THYMOCYTE; THYROIDITIS; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANIMALS; AUTOIMMUNE DISEASES; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNOLOGIC FACTORS; MALE; TISSUE DISTRIBUTION;

EID: 79959953337     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796117595     Document Type: Article

References (288)

1. Poletaev, A.B.; Stepanyuk, V.L.; Gershwin, M.E. Integrating immunity: the immunculus and self-reactivity. J. Autoimmun., 2008, 30, 68-73.
2. Wing, K.; Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T.; Miyara, M.; Fehervari, Z.; Sakaguchi, S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322, 271-275.
3. Bettelli, E.; Korn, T.; Oukka, M.; Kuchroo, V.K. Induction and effector functions of T(H)17 cells. Nature, 2008, 453, 1051-1057.
4. Bouneaud, C.; Kourilsky, P.; Bousso, P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: A large fraction of T cell clones escapes clonal deletion. Immunity, 2000, 13, 829-840.
5. Wu, Y.; Zheng, Z.; Jiang, Y.; Chess, L.; Jiang, H. The specificity of T cell regulation that enables self-nonself discrimination in the periphery. Proc. Natl. Acad. Sci. USA, 2009, 106, 534-539.
6. Murphy, K.M.; Reiner, S.L. The lineage decisions of helper T cells. Nat. Rev. Immunol., 2002, 2, 933-944.
7. Abbas, A.K.; Murphy, K.M.; Sher, A. Functional diversity of helper T lymphocytes. Nature, 1996, 383, 787-793.
8. Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med., 2007, 13, 139-145.
9. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol., 2009, 27, 485-517.
10. Zhou, L.; Lopes, J.E.; Chong, M.M.; Ivanov, I.I.; Min, R.; Victora, G.D. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature, 2008, 453, 236-240.
11. De León-Nava, M.A.; Nava, K.; Soldevila, G.; López-Griego, L.; Chávez-Ríos, J.R.; Vargas-Villavicencio, J.A.; Morales-Montor J. Immune sexual dimorphism: Effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation. J. Steroid. Biochem. Molecu. l Biol., 2009, 113, 57-64.
12. Tait, A.S.; Butts, C.L.; Sternberg, E.M. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J. Leukoc. Biol., 2008, 84, 924-931.
13. Olsen, N.J.; Kovacs, W.J. Gonadal steroids and immunity. Endocr. Rev., 1996, 17, 369-384.
14. Marriott, I; Huet-Hudson, Y.M. Sexual dimorphism in innate immune responses to infectious organisms. Immunol. Res., 2006, 34, 177-192.
15. Pearce, M.S.; Parker, L. Childhood cancer registrations in the developing world: still more boys than girls. Int. J. Cancer, 2001, 91, 402-406.
16. Ter Horst, G.J.; Wichmann, R.; Gerrits, M.; Westenbroek, C.; Lin, Y. Sex differences in stress responses: Focus on ovarian hormones. Physiol. Behav., 2009, 97, 239-249.
17. Ansar Ahmed, S.; Penhale, W.J.; Talal, N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am. J. Pathol., 1985, 121, 531-551.
18. Whitacre, C.C.; Reingold, S.C.; O'Looney, P.A. A gender gap in autoimmunity. Science, 1999, 283, 1277-1278.
19. Zandman-Goddard, G.; Peeva, E.; Shoenfeld, Y. Gender and autoimmunity. Autoimm. Rev., 2007, 6, 366-372.
20. Cutolo, M.; Straub, R.H. Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthr. Res. Ther., 2009, 11, 218-223.
21. Verthelyi, D. Sex hormones as immunomodulators in health and disease. Int. Immunopharmacol., 2001, 1, 983-993.
22. Butterworth, M.; McClellan, B.; Allansmith, M. Influence of sex in immunoglobulin levels. Nature, 1967, 214, 1224-1225.
23. Amadori, A.; Zamarchi, R.; De Silvestro, G.; Forza, G.; Cavatton, G.; Clementi, M.; Chieco-Bianchi, L. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat. Med., 1995, 1, 1279-1283.
24. Mylvaganam, R.; Ahn, Y.S.; Harrington, W.J.; Kim, C.I.; Gratzner, H.G. Differences in T cell subsets between men and women with idiopathic thrombocytopenic purpura. Blood, 1985, 66, 967-971.
25. Vottero, A.; Rochira, V.; Capelletti, M.; Viani, I.; Zirilli, L.; Neri, T.M.; Carani, C.; Bernasconi, S.; Ghizzoni, L. Aromatase is differ entially expressed in peripheral blood leukocytes from children, and adult female and male subjects. Eur. J. Endocrinol., 2006, 154, 425-431.
26. Yacoub Wasef, S.Z. Gender differences in systemic lupus erythematosus. Gend. Med., 2004, 1, 12-17.
27. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science, 1988, 240, 889-95.
28. McKay, L.; Cidlowski, J. Molecular control of immune/inflammatory responses: interactions between NF-kB and steroid receptor-signaling pathways. Endocr. Rev., 1999, 20, 435-459.
29. Vasudevan, N.; Pfaff, D.W. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr. Rev., 2007, 28, 1-19.
30. Wade, C.B.; Robinson, S.; Shapiro, R.A.; Dorsa, D.M. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase. Endocrinology, 2001, 142, 2336-2342.
31. Yager, J.D.; Chen, J.Q. Mitochondrial estrogen receptors-new insights into specific functions. Trends Endocrinol. Metab., 2007,18, 89-91.
32. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307, 1625-1630.
33. Revankar, C.M.; Mitchell, H.D.; Field, A.S.; Burai, R.; Corona, C.; Ramesh, C.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem. Biol., 2007, 2, 536-544.
34. Toran-Allerand, C.D.; Guan X, MacLusky, N.J.; Horvath, T.L.; Diano, S.; Singh, M.; Nethrapalli, I.S.; Tinnikov, A.A. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci., 2002, 22, 8391-401.
35. Enmark, E.; Gustafsson, J. A Oestrogen receptors-an overview. J. Intern. Med., 1999, 246, 133-138.
36. Edwards, D.P. Regulation of signal transduction pathways by estrogen and progesterone. Ann. Rev. Physiol., 2005, 67, 335-376.
37. Nilsson, B.; Bergqvist, A.; Lindblom, D.; Ljungberg, O.; Sodergard, R.; von Schoultz, B. Characterization and localization of specific oestrogen binding in the human thymus. Gynecol. Obstet. Invest., 1986, 21, 150-157.
38. Suenaga, R.; Evans, M.J.; Mitamura, K.; Rider, V.; Abdou, N.I. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J. Rheumatol., 1998, 25, 1305-1312.
39. Benten, W.P.M.; Stephan, C.; Wunderlich, F. B cells express intracellular but not surface receptors for testosterone and estradiol. Steroids, 2002, 67, 647-654.
40. Murphy, A.M.; Guyre, P.M.; Wira, C.R.; Pioli, P.A. Estradiol regulates expression of estrogen receptor ERa46 in human macrophages. PLoS One, 2009, 4, e5539.
41. Mor, G.; Sapi, E.; Abrahams, V.M.; Rutherford, T.; Song, J.; Hao, X.Y.; Muzaffar, S.; Kohen, F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol., 2003, 170, 114-122.
42. Staples, J.E.; Gasiewitcz, T.A.; Fiore, N.C.; Lubahn, D.B.; Korach, K.S.; Silverstone, A.E. Estrogen receptor α is necessary in thymic development and estradiol-induced thymic alterations. J. Immunol., 1999, 163, 4168-4174.
43. Yellayi, S.; Teuscher, C.; Woods, J.A.; Welsh, T.H.; Tung, K.S.; Nakai, M.; Rosenfeld, C.S.; Lubahn, D.B.; Cooke, P.S. Normal development of thymus in male and female mice requires estrogen/estrogen receptor-alpha signaling pathway. Endocrine, 2000, 12, 207-213.
44. Erlandsson, M.C.; Ohlsson, C.; Gustafsson, J.A.; Carlsten, H. Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology, 2001, 103, 17-25.
45. Smithson, G.; Medina, K.; Ponting, I.; Kincade, P.W. Estrogen suppresses stromal cell-dependent lymphopoiesis in culture. J. Immunol., 1995, 155, 3409-3417.
46. Smithson, G.; Couse, J.F.; Lubahn, D.; Korach, K.S.; Kincade, P.W. The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. J. Immunol., 1998, 161, 27-34.
47. Polanczyk, M.J.; Hopke1, C.; Vandenbark, A.A.; Offner, H. Treg suppressive activity involves estrogen dependent expression of programmed death-1 (PD-1). Intern. Immunol., 2007, 19, 337-343.
48. Benten, W.P.M.; Lieberherr, M.; Giese, G.; Wunderlich, F. Estradiol binding to cell surface raises cytosolic free calcium in T cells. FEBS Lett., 1998, 422, 349-53.
49. Benten, W.P.M.; Stephan, C.; Lieberherr, M.; Wunderlich, F. Estradiol signaling via sequestrable surface receptors. Endocrinology, 2001, 142, 1669-77.
50. Misrahi, M.; Venencie, P.Y.; Saugier-Veber, P.; Sar, S.; Dessen, P.; Milgrom, E. Structure of the human progesterone receptor gene. Biochim. Biophys. Acta, 1993, 1216, 289-292.
51. Szekeres-Bartho, J.; Polgar, B.; Kozma, N.; Miko, E.; Par, G.; Barakonyi, A.; Palkovics, T.; Papp, O.; Varga, P. Progesteronedependent immunomodulation. Chem. Immunol. Allergy, 2005, 89, 118-125.
52. Butts, C.L.; Shukair, S.A.; Duncan, K.M.; Bowers, E.; Horn, C.; Belyavskaya, E.; Tonelli, L.; Sternberg, E.M. Progesterone inhibits mature rat dendritic cells in a receptor mediated fashion. Int. Immunol., 2007, 19, 287-296.
53. Szekeres-Bartho, J.; Weill, B.J.; Mike, G.; Houssin, D.; Chaouat, G. Progesterone receptors in lymphocytes of liver-transplanted and transfused patients. Immunol. Lett., 1989, 22, 259-261.
54. Butts, C.; Bowers, E.; Horn, C.; Shukair, S.A.; Belyavskaya, E.; Sternberg, E.M. Inhibitory effects of progesterone differ in dendritic cells from female and male rodents. Gender. Med., 2008, 5, 434-447.
55. Janssen, O.E.; Mehlmauer, N.; Hahn, S.; Gartner, R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur. J. Endocrinol., 2004, 150, 363-369.
56. Lydon, J.P.; DeMayo, F.J.; Funk, C.R.; Mani, S.K.; Hughes, A.R.; Montgomery, C.A.; Shyamala, G.; Conneely, O.M.; O'Malley, B.W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev., 1995, 9, 2266-2278.
57. Dosiou, C.; Hamilton, A.E.; Pang, Y.; Overgaard, M.T.; Tulac, S.; Dong, J.; Thomas, P.; Giudice, L.C. Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J. Endocrinol., 2008, 196, 67-77.
58. Chang, C.S.; Kokontis, J.; Liao, T. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl. Acad. Sci. USA, 1988, 85, 7211-7215.
59. Bellido, T.; Jilka, R.L.; Boyce, B.F.; Girasole, G.; Broxmeyer, H.; Dalrymple, S.A.; Murray, R.; Manolagas, S.C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest., 1995, 95, 2886-2895.
60. Kovacs, W.; Olsen, N. Androgen receptors in human thymocytes. J. Immunol., 1987, 139, 490-493.
61. Olsen, N.J.; Kovacs, W.J. Effects of androgens on T and B lymphocyte development. Immunol. Res., 2001, 23, 281-288.
62. Liva, S.M.; Voskuhl, R.R. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J. Immunol., 2001, 167, 2060-2067.
63. Danel, L.; Vincent, C.; Rousset, F.; Klein, B.; Bataille, R.; Flacher, M.; Durie, B.G.; Revillard, J.P. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J. Steroid. Biochem., 1988, 30, 363-7.
64. Benten, W.P.; Lieberherr, M.; Stamm, O.; Wrehlke, C.; Guo, Z.; Wunderlich, F. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol. Biol. Cell, 1999, 10, 3113-3123.
65. Wunderlich, F.; Benten, W.P.; Lieberherr, M.; Guo, Z.; Stamm, O.; Wrehlke, C.; Sekeris, C.E.; Mossmann, H. Testosterone signaling in T cells and macrophages. Steroids, 2002, 67, 535-538.
66. Benten, W.P.; Guo, Z.; Krücken, J.; Wunderlich, F. Rapid effects of androgens in macrophages. Steroids, 2004, 69, 585-590.
67. Chuang, K.H.; Altuwaijr, S.; Li, G.; Lai, J.J.; Chu, C.Y.; Lai, K.P.; Lin, H.Y.; Hsu, J.W.; Keng, P.; Wu, M.C.; Chang, C. Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J. Exp. Med., 2009, 206, 1181-1199.
68. Hall, J.M.; McDonnell, D.P. The estrogen receptor α-isoform (ERα) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 1999, 140, 5566-5578.
69. Straub, R.H. The complex role of estrogens in inflammation. Endocr. Rev., 2007, 28, 521-574.
70. Paavonen, T.; Anderson, L.C.; Adlercreutz, H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J. Exp. Med., 1981, 154, 1935-1945.
71. Ansar, A.S.; Dauphinee, M.J.; Montoya, A.I.; Talal, N. Estrogen induces normal murine CD5+ B cells to produce autoantibodies. J. Immunol., 1989, 142, 2647-2653.
72. Okuyama, R.; Abo, T.; Seki, S.; Ohteki, T.; Kusumi, A.; Kumagai, K. Estrogen administration activates extrathymic T cell differentiation in the liver. J. Exp. Med., 1992, 175, 661-669.
73. Leposavic, G.; Obradovic, S.; Kosec, D.; Pejcic-Karapetrovic, B.; Vidic-Dankovic, B. In vivo modulation of the distribution of thymocyte subsets by female sex steroid hormones. Intern. Immunopharmacol., 2001, 1, 1-12.
74. Staples, J.E.; Gasiewicz, T.A.; Fiore, N.C.; Lubahn, D.B.; Korach, K.S.; Silverstone, A.E. Estrogen receptor α is necessary in thymic development and estradiol-induced thymic alterations. J. Immunol., 1999, 163, 4168-4174.
75. Erlandsson, M.C.; Ohlsson, C.; Gustafsson, J.A.; Carlsten, H. Role of oestrogen receptors α and β in immune organ development and in oestrogen-mediated effects on thymus. Immunology, 2001, 103, 17-25.
76. Wang, C.; Dehghani, B.; Magrisso, I.J.; Rick, E.A.; Bonhomme, E.; Cody, D.B.; Elenich, L.A.; Subramanian, S.; Murphy, S.J.; Kelly, M.J.; Rosenbaum, J.S.; Vandenbark, A.A.; Offner, H. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 2008, 22, 636-648.
77. Venkatesh, J.; Peeva, E.; Xu, X.; Diamond, B. Cutting edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J. Immunol., 2006, 176, 3311-3314.
78. Smithson, G.; Medina, K.; Ponting, I.; Kincade, P.W. Estrogen suppresses stromal cell-dependent lymphopoiesis in culture. J. Immunol., 1995, 155, 3409-3417.
79. Peeva, E.; Venkatesh, J.; Diamond, B. Tamoxifen blocks estrogeninduced B cell maturation but not survival. J. Immunol., 2005, 175, 1415-1423.
80. Peeva, E.; Zoualib, M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol. Lett., 2005, 101, 123-143.
81. Verthelyi, D.; Ahmed, S.A. 17-beta-estradiol, but not 5-alphadihydrotestosterone, augments antibodies to double-stranded deoxyribonucleic acid in non-autoimmune C57BL/6J mice. Endocrinology, 1994, 135, 2615-2622.
82. Verthelyi, D.; Ansar, A.S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmunity, 1997, 10, 115-125.
83. Kanda, N.; Tamaki, K. Estrogen enhances immunoglobulin production by human PBMCs. J. Allergy Clinic. Immunol., 1999, 103, 282-288.
84. Maret, A.; Coudert, J.D.; Garidou, L.; Foucras, G.; Gourdy, P.; Krust, A.; Dupontm S.; Chambon, P.; Druet, P.; Bayard, F.; Guery, J.C. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor α expression in hematopoietic cells. Eur. J. Immunol., 2003, 33, 512-521.
85. Fox, H.S.; Bond, B.L.; Parslow, T.G. Estrogen regulates the IFNgamma promoter. J. Immunol., 1991, 146, 4362-4367.
86. Karpuzoglu-Sahin, E.; Hissong, B.D.; Ansar Ahmed, S. Interferongamma levels are upregulated by 17-beta-estradiol and diethylstilbestrol. J. Reprod. Immunol., 2001, 52,113-127.
87. Lambert, K.C.; Curran, E.M.; Judy, B.M.; Milligan, G.N.; Lubahn, D.B.; Estes, D.M. Estrogen receptor α (ERα) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17β-estradiol acts through ERα to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. J. Immunol., 2005, 175, 5716-5723.
88. Polanczyk, M.J.; Carson, B.D.; Subramanian, S.; Afentoulis, M.; Vandenbark, A.A.; Ziegler, S.F.; Offner, H. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol., 2004, 173, 2227-2230.
89. Tai, P.; Wang, J.; Jin, H.; Song, X.; Yan, J.; Kang, Y.; Zhao, L.; An, X.; Du, X.; Wang, S.; Xia, G.; Wang, B. Induction of regulatory T cells by physiological level estrogen. J. Cell. Physiol., 2008, 214, 456-464.
90. Oursler, M.J.; Cortese, C.; Keeting, P.; Anderson, M.A.; Bonde, S.K.; Riggs, B.L.; Spelsberg, T.C. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology, 1991, 129, 3313-3320.
91. Souwenne, G.; Danel, L.; Costa, O.; Tubiana, N.; Martin, P.; Monier, J.C.; Saez, S. Effect of physiological concentrations of sex hormones on the formation of early sheep red blood cell rosettes by human lymphocytes: possible reltions with the presence of sexhormone-cytosol-receptors in lymphocytes. Biomed. Express., 1980, 33, 150-152.
92. Arruvito, L.; Sanz, M.; Banham, A.H.; Fainboim, L. Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J. Immunol., 2007, 178, 2572-2578.
93. McKay, L.I.; Cidlowski, J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factorkB and steroid receptor-signaling pathways. Endocr. Rev., 1999, 20, 435-459.
94. Rogers, A.; Eastell, R. The effect of 17-β estradiol on production of cytokines in cultures of peripheral blood. Bone, 2001, 29, 30-34.
95. Rodriguez, E.; Lopez, R.; Paez, A.; Masso, F.; Montano, L.F. 17β Estradiol inhibits the adhesion of leukocytes in TNF-α stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its transcription. Life Sci., 2001, 71, 2181-2193.
96. An, J.; Ribeiro, R.C.J.; Webb, P.; Gustafsson, J.A.; Kushner, P.J.; Baxter, J.D.; Leitman, D.C. Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. USA, 1999, 96, 15161-15166.
97. Canellada, A.; Alvarez, I.; Berod, L.; Gentile, T. Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells. J. Steroid Biochem. Molec. Biol., 2008, 111, 255-261.
98. Yamada, K.; Hayashi, T.; Kuzuya, M.; Naito, M.; Asai, K.; Iguchi, A. Physiological concentration of 17β-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery, 1996, 22, 24-35.
99. Janis, K.; Hoeltke, J.; Nazareth, M.; Fanti, P.; Poppenberg, K.; Aronica, S.M. Estrogen decreases expression of chemokine receptors, and suppresses chemokine bioactivity in murine monocytes. Am. J. Reprod. Immunol., 2004, 51, 22-31
100. Straub, R.H. The Complex Role of Estrogens in Inflammation. Endocr. Rev., 2007, 28, 521-574.
101. Ruh, M.F.; Bi, Y.; D'Alonzo, R.; Bellone, C.J. Effect of estrogens on IL-1α promoter activity. J. Steroid Biochem. Mol. Biol., 1998, 66, 203-210.
102. Polan, M. L,; Daniele, A.; Kuo, A. Gonadal steroids modulate human monocyte interleukin-1 (IL-1) activity. Fertil. Steril., 1988, 49, 964-968.
103. Keller E.T.; Zhang, J.; Yao, Z.; Qi, Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause. J. Reprod. Immunol., 2001, 50, 41-55.
104. Warri, A.; Kangas, L. Effect of toremifene on the activity of NKcells in NZB/NZW mice. J. Steroid Biochem., 1990, 36, 207-209.
105. Chantakru, S.; Wang, W.C.; van Den, H.M.; Bashar, S.; Simpson, A.; Chen, Q.; Croy, B.A.; Evans, S.S. Coordinate regulation of lymphocyte endothelial interactions by pregnancy-associated hormones. J. Immunol., 2003, 171, 4011-4019.
106. Caulin-Glaser, T., Watson, C.A.; Pardi, R.; Bender, J.R. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J. Clin. Invest., 1996, 98, 36-42.
107. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c+CD11b intermediate dendritic cells from bone marrow precursors. J. Immunol., 2004, 172, 1426-1436.
108. Cutolo, M.; Capellino, S.; Montagna, P.; Ghiorzo, P.; Sulli, A.; Villaggio, B. Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res. Ther., 2002, 7, R1124-R1132.
109. Rubanyi, G.M.; Johns, A.; Kauser, K. Effect of estrogen on endothelial function and angiogenesis. Vascul. Pharmacol., 2002, 38, 89-98.
110. Yang, J.H.; Chen, C.D.; Wu, M.Y.; Chao, K.H.; Yang, Y.S.; Ho, H.N. Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women. Fertil. Steril. 2000, 74, 261-267.
111. Weidler, C.; Harle, P.; Schedel, J.; Schmidt, M.; Scholmerich, J.; Straub, R.H. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol., 2004, 31, 489-494.
112. Holmdahl, R.; Carlsten, H.; Jansson, L.; Larsson, P. Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br. J. Rheumatol., 1989, 28(Suppl 1), 54-58.
113. Wehling, M.; Schultz, A.; Losel, R. To be or not to be (a receptor). Steroids, 2007, 72, 107-110.
114. Chao, T.C.; Phuangsab, A.; Van Alten, P.J.; Walter R.J. Steroid sex hormones and macrophage function: regulation of chemiluminescence and phagocytosis. Am. J. Reprod. Immunol., 1996, 35, 106-113.
115. Piccinni, M.P.; Giudizi, M.G.; Biagiotti, R.; Beloni, L.; Giannarini, L.; Sampognaro, S.; Parronchi, P.; Manetti, R.; Annunziato, F.; Livi, C. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol., 1995, 155, 128-133.
116. Lance Miller, L.; Hunt, J.S. Regulation of TNF-α production in activated mouse macrophages by progesterone. J. Immunol., 1998, 160, 5098-5104.
117. Szekeres-Bartho, J.; Wegmann, T.G. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol., 1996, 31, 81-95.
118. Le, N.; Yousefi, S.; Vaziri, N.; Carandang, G.; Ocariz, J.; Cesario, T. The effect of α-estradiol, progesterone and testosterone on the production of human leukocyte derived interferons. J. Biol. Regul. Homeost. Agents, 1988, 2, 199-204.
119. Szekeres-Bartho, J.; Kinsky, R.; Chaouat, G. The effect of a progesterone-induced immunologic blocking factor on NK-mediated resorption. Am. J. Reprod. Immunol., 1990, 24, 105-107.
120. Butts, C.L.; Shukair, S.A.; Duncan, K.M.; Bowers, E.; Horn, C.; Belyavskaya, E.; Tonelli, L.; Sternberg, E.M. Progesterone inhibits mature rat dendritic cells in a receptor mediated fashion. Int. Immunol., 2007, 19, 287-296.
121. Correale, J.; Arias, M.; Gilmore, W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol., 1998, 161, 3365-3374.
122. Miyaura, H.; Iwata, M. Direct and indirect inhibition of Th1development by progesterone and glucocorticoids. J. Immunol., 2002, 168, 1087-1094.
123. Godbout, J.P.; Glaser, R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J. Neuroimmune Pharmacol., 2006, 1, 421-427.
124. Guevara Patino, J.A.; Marino, M.; Ivanov, V.N.; Nikolich-Zugich, J. Sex steroids induce apoptosis of CD8+CD4+ double-positive thymocytes via TNF-alpha. Eur. J. Immunol., 2000, 30, 2586-2592.
125. Fitzpatrick, F.T.; Kendall, M.D.; Wheeler, M.J.; Adcock, I.M.; Greenstein, B.D. Reappearance of thymus of ageing rats after orchidectomy. J. Endocrinol. 1985, 106, R17-R19.
126. Kanda, N.; Tsuchida, T.; Tamaki, K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin. Exp. Immunol., 1996, 106, 410-415.
127. Rettew, J.A.; Huet-Hudson, Y.M.; Marriott, I. Testosterone reduces macrophage expression in the mouse of Toll-like receptor 4, a trigger for inflammation and innate immunity. Biol. Reproduct., 2008, 78, 432-437.
128. Page, S.T.; Plymate, S.R.; Bremner, W.J.; Matsumoto, A.M.; Hess, D.L.; Lin, D.W.; Amory, J.K.; Nelson, P.S.; Wu, J.D. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFNgamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E856-863.
129. Loria, R.M.; Padgett, D.A. Control of the immune response by DHEA and its metabolites. Rinsho. Byori., 1998, 46, 505-517.
130. Daynes, R.A.; Dudley, D.J.; Araneo, B.A. Regulation of murine lymphokine production in vivo. II Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur. J. Immunol., 1990, 20, 793-802.
131. Daynes, R.A.; Araneo, B.A.; Ershler, W.B.; Maloney, C.; Li, G.Z.; Ryu, S.Y. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J. Immunol., 1993, 150, 5219-5230.
132. Druckmann, R.; Druckmann, M.A. Progesterone and the immunology of pregnancy. J. Steroid Biochem. Molecul. Biol., 2005, 97, 389-396.
133. Vargas-Villavicencio, J.A.; De León-Nava, M.A.; Morales-Montor, J. Immunoendocrine mechanisms associated with resistance or susceptibility to parasitic diseases during pregnancy. Neuroimmunomodulation, 2009, 16, 114-121.
134. Doria, A.; Iaccarino, L.; Arienti, S.; Ghirardello, A.; Zampieri, S.; Rampudda, M.E.; Cutolo, M.; Tincani, A.; Todesco, S. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reproduct. Toxicol., 2006, 22, 234-241.
135. Polanczyk, M.J.; Hopke, C.; Huan, J.; Vandenbark, A.A.; Offner, H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol., 2005, 30, 170, 85-92.
136. Lahita, R.G. The influence of sex hormones on the disease systemic lupus erythematosus. Springer Semin. Immunopathol., 1986, 9, 305-314.
137. Lahita, R.G.; Bradlow, H.L.; Fishman, J.; Kunkel, H.G. Abnormal estrogen and androgen metabolism in the human with systemic lupus erythematosus. Am. J. Kidney Dis., 1982, 2, 206-211.
138. Holmdahl, R. Estrogen exaggerates lupus but suppresses T-celldependent autoimmune disease. J. Autoimmunity, 1989, 2, 651-656.
139. Schmidt, M.; Kreutz, M.; Loffler, G.; Scholmerich, J.; Straub, R.H. Conversion of dehydroepi-androsterone to downstream steroid hormones in macrophages. J. Endocrinol., 2000, 164, 161-169.
140. Pacifici, R., Brown, C.; Puscheck, E.; Friedrich, E.; Slatopolsky, E.; Maggio, D.; McCracken, R.; Avioli, L.V. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA, 1991, 88, 5134-5138.
141. Pfeilschifter, J.; Koditz, R.; Pfohl, M.; Schatz, H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev., 2002, 23, 90-119.
142. Cantatore, F.P.; Loverro, G.; Ingrosso, A.M.; Lacanna, R.; Sassanelli, E.; Selvaggi, L.; Carrozzo, M. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin. Rheumatol., 1995, 14, 157-160.
143. Ralston, S.H.; Russell, R.G.; Gowen, M. Estrogen inhibits release of TNF from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res., 1990, 5, 983-988.
144. Bernard-Poenaru, O.; Roux, C.; Blanque, R.; Gardner, C.; de Vernejoul, M.C.; Cohen-Solal, M.E. Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study. Osteoporos. Int., 2001, 12, 769-776.
145. Masi, A.T.; Kaslow, R.A. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum., 1978, 21, 480-484.
146. Lahita, R.G. The role of sex hormones in systemic lupus erythematosus. Curr. Opin. Rheumatol. 1999, 11, 352-356.
147. Cohen-Solal, J.F.; Jeganathan, V.; Grimaldi, C.M.; Peeva, E.; Diamond, B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol., 2006, 305, 67-88.
148. Kanda, N.; Tsuchida, T.; Tamaki, K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum., 1999, 42, 328-337.
149. Jacobi, A.M.; Zhang, J.; Mackay, M.; Aranow, C.; Diamond, B. Phenotypic characterization of autoreactive B cells-checkpoints of B cell tolerance in patients with systemic lupus erythematosus. PLoS One, 2009, 4, e5776.
150. Khan, W.A.; Uddin, M.; Khan, M.W.; Chabbra, H.S. Catecholoestrogens: possible role in systemic lupus erythematosus. Rheumatology, 2009, 48, 1345-1351.
151. Rider, V., Abdou, N.I. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int. Immunopharmacol., 2001, 1, 1009-1024.
152. Lee, H.M.; Mima, T.; Sugino, H.; Aoki, C.; Adachi, Y.; Yoshio-Hoshino, N.; Matsubara, K.; Nishimoto, N. Interactions among type I and type II interferon, tumor necrosis factor, and betaestradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res. Ther., 2009, 11, R1 Epub.
153. Walters, E.; Rider, V.; Abdou, N.I.; Greenwell, C.; Svojanovsky, S:, Smith, P.; Kimler, B.F. Estradiol targets T cell signaling pathways in human systemic lupus. Clin. Immunol., 2009, 133, 428-436.
154. Rider, V.; Li, X.; Peterson, G.; Dawson, J.; Kimler, B.F.; Abdou, N.I. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J. Rheumatol., 2006, 33, 1093-1101.
155. Rider, V.; Jones, S.; Evans, M.; Bassiri, H.; Afsar, Z.; Abdou, N.I. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J. Rheumatol., 2001, 28, 2644-2649.
156. Cohen-Solal, J.F.; Jeganathan, V.; Grimaldi, C.M.; Peeva, E.; Diamond, B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol., 2006, 305, 67-88.
157. Siiteri, P.K.; Jones, L.A.; Roubinian, J.; Talal, N. Sex steroids and the immune system-I. Sex difference in autoimmune disease in NZB/NZW hybrid mice. J. Steroid Biochem. Mol. Biol., 1980, 12, 425-432.
158. Feng, F.; Nyland, J.; Banyai, M.; Tatum, A.; Silverstone, A.E.; Gavalchin, J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol., 2010, 134, 226-236.
159. Roubinian, J.R.; Papoian, R.; Talal, N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clinic. Invest., 1977, 59, 1066-1070.
160. Talal, N. Natural history of murine lupus. Modulation by sex hormones. Arthritis Rheum., 1978, 21, S58-63.
161. Walker, S.E.; Besch-Williford, C.L.; Keisler, D.H. Accelerated deaths from systemic lupus erythematosus in NZB x NZW F1 mice treated with the testosterone-blocking drug flutamide. J. Lab. Clin. Med., 1994, 124, 401-407.
162. Carlsten, H.; Nilsson, N.; Jonsson, R.; Backman, K.; Holmdahl, R.; Tarkowski, A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell. Immunol., 1992, 144, 190-202.
163. Weidler, C.; Harle, P.; Schedel, J.; Schmidt, M.; Scholmerich, J.; Straub, R.H. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol., 2004, 31, 489-494.
164. Kocar, I.H.; Yesilova, Z.; Ozata, M.; Turan, M.; Sengul, A.; Ozdemir, I. The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome. Clinic. Exp. Immunol., 2000, 121, 448-452.
165. Lahita, R.G.; Bradlow, H.L.; Ginzler, E.; Pang, S.; New, M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum., 1987, 30, 241-248.
166. Folomeev, M.; Dougados, M.; Beaune, J. Plamsa sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus, 1992, 1, 191-195.
167. Piotrowski, P.; Gasik, R.; Lianeri, M.; Cieślak, D.; Wudarski, M.; Hrycaj, P.; La{ogonek}cki, J.K.; Jagodziński, P.P. Asp327Asn polymorphism of sex hormone-binding globulin gene is associated with systemic lupus erythematosus incidence. Mol. Biol. Rep., 2009, 37(1), 235-239.
168. Genelabs Technologies I. GL701 (DHEA, prasterone) for the treatment of systemic lupus erythematosus (SLE) in women. Briefing Document FDA Arthritis Advisory Committee. Briefing Document, FDA Arthritis Advisory Committee 2001.
169. Sanchez-Guerrero, J.; Uribe, A.G.; Jimenez-Santana, L.; Mestanza-Peralta, M.; Lara-Reyes, P.; Seuc, A.H.; Cravioto, M.D. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med., 2005, 353, 2539-2549.
170. Bernier, M.O.; Mikaeloff, Y.; Hudson, M.; Suissa, S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum., 2009, 61, 476-481.
171. Holroyd, C.R.; Edwards, C.J. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric, 2009, 12, 378-386.
172. Doria, A.; Ghirardello, A.; Iaccarino, L.; Zampieri, S.; Punzi, L.; Tarricone, E.; Ruffatti, A.; Sulli, A.; Sarzi-Puttini, P.C.; Gambari, P.F.; Cutolo, M. Pregnancy, cytokines and disease activity in systemic lupus erythematosus. Arthritis Rheum., 2004, 51, 989-995.
173. Gimovsky, M.L.; Montoro, M. Systemic lupus erythematosus and other connective tissue diseases in pregnancy. Clin. Obstet. Gynecol., 1991, 34, 35-50.
174. Khamashta, M.A.; Ruiz-Irastorza, G.; Hughes, G.R. Systemic lupus erythematosus flares during pregnancy. Rheum. Dis. Clin. N. Am., 1997, 23, 15-30.
175. Doria, A.; Cutolo, M.; Ghirardello, A.; Zampieri, S.; Vescovi, F.; Sulli, A.; Giusti, M.; Piccoli, A.; Grella, P.; Gambari, P.F. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum., 2002, 47, 202-209.
176. Van Vollenhoven, R.F.; Morabito, L.M.; Engleman, E.G.; McGuire, J.L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J. Rheumatol., 1998, 25, 285-289.
177. Nordmark, G.; Bengtsson, C.; Larsson, A.; Karlsson, F.A.; Sturfelt, G.; Ronnblom, L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity, 2005, 38, 531-540.
178. Petri, M.A.; Lahita, R.G.; Van Vollenhoven, R.F.; Merrill, J.T.; Schiff, M.; Ginzler, E.M.; Strand, V.; Kunz, A.; Gorelick, K.J.; Schwartz, K.E.; GL601 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum., 2002, 46, 1820-1829.
179. Crosbie, D.; Black, C.; McIntyre, L.; Royle, P.L.; Thomas, S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst. Rev., 2007, 17, CD005114.
180. Gordon, C.; Wallace, D.J.; Shinada, S.; Kalunian, K.C.; Forbess, L., Braunstein, G.D.; Weisman, M.H. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology, 2008, 47, 334-338.
181. Abdou, N.I.; Rider, V.; Greenwell, C.; Li, X.; Kimler, B.F. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J. Rheumatol., 2008, 35, 797-803.
182. Mok, C.C.; To, C.H.; Mak, A.; Ma, K.M. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum., 2005, 52, 3997-4002.
183. Vieira, C.S.; Pereira, F.V.; de Sá, M.F.; Paulo, L.J.; Martins, W.P.; Ferriani, R.A. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study. Maturitas, 2009, 62, 311-316.
184. El-Etr, M.; Vukusic, S.; Gignoux, L.; Durand-Dubief, F.; Achiti, I.; Baulieu, E.E.; Confavreux, C. Steroid hormones in multiple sclerosis. J. Neurol. Sci., 2005, 233, 49-54.
185. Nicot, A.B. Gender and sex hormones in multiple sclerosis pathology and therapy. Front. Biosci., 2009, 14, 4477-4515.
186. Runmarker, B.; Andersen, O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain, 1993, 116, 117-134.
187. Pozzilli, C.; Tomassini, V.; Marinelli, F.; Paolillo, A.; Gasperini, C.; Bastianello, S. Gender gap in multiple sclerosis: magnetic resonance imaging evidence. Eur. J. Neurol., 2003, 10, 95-97.
188. Calabrese, M.; De Stefano, N.; Atzori, M.; Bernardi, V.; Mattisi, I.; Barachino, L.; Morra, A.; Rinaldi, L.; Romualdi, C.; Perini, P.; Battistin, L.; Gallo, P. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch. Neurol., 2007, 64, 1416-1422.
189. Segal, B.M.; Shevach, E.M. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med., 1996, 184, 771-775.
190. Langrish, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.; Kastelein, R.A.: Cua, D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med., 2005, 201, 233-240.
191. Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M. Interleukin-17 production in central nervous systeminfiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol., 2008, 172, 146-155.
192. Vaknin-Dembinsky, A.; Balashov, K.; Weiner, H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol., 2006, 176, 7768-7774.
193. Buenafe, A.C.; Andrew, S.; Afentoulis, M.; Offner, H.; Vandenbark, A.A. Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) FoxP3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells. Immunol., 2010, 130(1),114-124.
194. Wang, C.; Li, Y.; Proctor, T.M.; Vandenbark, A.A.; Offner, H. Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J. Neurosci. Res., 2010, 88, 7-15.
195. Voskuhl, R.R.; Palaszynski, K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist, 2001, 7, 258-270.
196. Bebo, B.F.; Vandenbark, A.A.; Offner, H. Male SJL mice do not relapse after induction of EAE with PLP 139-151. J. Neurosci. Res., 1996, 45, 680-689.
197. Bebo, B.F.; Zelinka-Vincent, E.; Adamus, G.; Amundson, D.; Vandenbark, A.A.; Offner, H. Gonadal hormones influence the immune response to PLP 139-151 and the clinical course of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol., 1998, 84, 122-130.
198. Bebo, B.F.; Schuster, J.C.; Vandenbark, A.A.; Offner, H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J. Immunol., 1999, 162, 35-40.
199. Bebo, B.F.; Schuster, J.C.; Vandenbark, A.A.; Offner, H. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J. Neurosci. Res., 1998, 52, 420-426.
200. Sinha, S.; Kaler, L.J.; Proctor, T.M.; Teuscher, C.; Vandenbark, A.A.; Offner, H. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J. Immunol., 2008, 180, 2679-2685.
201. Bebo, B.F.; Adlard, K.; Schuster, J.C.; Unsicker, L.; Vandenbark, A.A.; Offner, H. Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. J. Neurosci. Res., 1999, 55, 432-440.
202. Jansson, L.; Olsson, T.; Holmdahl, R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J. Neuroimmunol., 1994, 53, 203-207.
203. Kim, S.; Liva, S.M.; Dalal, M.A., Verity, M.A.; Voskuhl, R.R. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology, 1999, 52, 1230-1238.
204. Zang, Y.C.; Halder, J.B.; Hong, J.; Rivera, V.M.; Zhang, J.Z. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kB. J. Neuroimmunol., 2002, 124, 106-114.
205. Hoffman, G.E.; Le, W.W.; Murphy, A.Z.; Koski, C.L. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rat. Exp. Neurol., 2001, 171, 272-284.
206. Offner, H.; Polanczyk, M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. N. Y. Acad. Sci., 2006, 1089, 343-372.
207. Bebo, B.F.; Fyfe-Johnson, A.; Adlard, K.; Beam, A.G.; Vandenbark, A.A.; Offner, H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol., 2001, 166, 2080-2089.
208. Holmqvist, P.; Wallberg, M.; Hammar, M.; Landtblom, A.M.; Brynhildsen, J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas, 2006, 54, 149-153.
209. Smith, R.; Studd, J.W. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J. R. Soc. Med., 1992, 85, 612-613
210. Confavreux, C.; Hutchinson, M.; Hours, M.M.; Cortinovis-Tourniaire, P.; Moreau, T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med., 1998, 339, 285-291.
211. Pozzilli, C.; Falaschi, P.; Mainero, C.; Martocchia, A.; D'Urso, R.; Proietti, A.; Frontoni, M.; Bastianello, S.; Filippi, M. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology, 1999, 53, 622-624.
212. Tomassini, V.; Onesti, E.; Mainero, C.; Giugni, E.; Paolillo, A.; Salvetti, M.; Nicoletti, F.; Pozzilli, C. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J. Neurol. Neurosurg. Psychiatry, 2005, 76, 272-275.
213. Falaschi, P.; Martocchia, A.; Proietti, A.; D'Urso, R.; Antonimi, G.; Pozzilli, C. The modulatory role of the sex steroid balance on the disease activity in female patients with multiple sclerosis. In: Focus on Multiple Sclerosis Research. Columbus F, Editor. Nova Science Publisher. 2004, 199-215.
214. Bansil, S.; Lee, H.J.; Jindal, S.; Holtz, C.R.; Cook, S.D. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol. Scand, 1999, 99, 91-94.
215. Zorgdrager, A.; De Keyser, J. The premenstrual period and exacerbations in multiple sclerosis. Eur. Neurol., 2002, 48, 204-206.
216. Zorgdrager, A.; De Keyser, J. Menstrually related worsening of symptoms in multiple sclerosis. J. Neurol. Sci., 1997, 149, 95-97.
217. Ito, A.; Bebo, B.F.; Matejuk, A.; Zamora, A.; Silverman, M.; Fyfe-Johnson, A.; Offner, H. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol., 2001, 167, 542-552.
218. Liu, H.Y.; Buenafe, A.C.; Matejuk, A.; Ito, A.; Zamora, A.; Dwyer, J.; Vandenbark, A.A.; Offner, H. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res., 2002, 70, 238-248.
219. Dhandapani, K.M.; Wade, F.M.; Mahesh, V.B.; Brann, D.W. Astrocyte-derived transforming growth factor-α mediates the neuroprotective effects of 17β-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology, 2005, 146, 2749-2759.
220. Bebo, B.F.; Fyfe-Johnson, A.; Adlard, K.; Beam, A.G.; Vandenbark, A.A.; Offner, H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol., 2001, 166, 2080-2089.
221. Polanczyk, M.J.; Carson, B.D.; Subramanian, S.; Afentoulis, M.; Vandenbark, A.A.; Ziegler, S.F.; Offner, H. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol., 2004, 173, 2227-2230.
222. Polanczyk, M.J.; Hopke, C.; Huan, J.; Vandenbark, A.A.; Offner, H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol., 2005, 170, 85-92.
223. Pettersson, A.; Ciumas, C.; Chirsky, V.; Link, H.; Huang, Y.M.; Xiao, B.G. Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis. J. Neuroimmunol., 2004, 156, 58-65.
224. Gilmore, W.; Weiner, L.P.; Correale, J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol., 1997, 158, 446-451
225. Polanczyk, M.J.; Hopke, C.; Vandenbark, A.A.; Offner, H. Treg suppressive activity involves estrogen dependent expression of programmed death-1 (PD-1). Intern. Immunol., 2007, 19, 337-343.
226. Wang, C.; Dehghani, B.; Li, Y.; Kaler, L.J.; Vandenbark, A.A.; Offner, H. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology, 2009, 126, 329-335.
227. Wang, C.; Dehghani, B.; Li, Y.; Kaler, L.J.; Proctor, T.; Vandenbark, A.A.; Offner, H. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J. Immunol., 2009, 182, 3294-3303.
228. Subramanian, S.; Matejuk, A.; Zamora, A.; Vandenbark, A.A.; Offner, H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J. Immunol., 2003, 170, 1548-1555.
229. Matejuk, A.; Adlard, K.; Zamora, A.; Silverman, M.; Vandenbark, A.A.; Offner, H. 17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J. Neurosci. Res., 2001, 65, 529-542.
230. Polanczyk, M.; Zamora, A.; Subramanian, S.; Matejuk, A.; Hess, D.L.; Blankenhorn, E.P.; Teuscher, C.; Vandenbark, A.A.; Offner, H. The protective effect of 17β-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-α. Am. J. Pathol., 2003, 163, 1599-1605.
231. Liu, H.B.: Loo, K.K.; Palaszynski, K.; Ashouri, J.; Lubahn, D.B.; Voskuhl, R.R. Estrogen receptor α mediates estrogen's immune protection in autoimmune disease. J. Immunol., 2003, 171, 6936-6940.
232. Elloso, M.M.; Phiel, K.; Henderson, R.A.; Harris, H.A.; Adelman, S.J. Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J. Endocrinol., 2005, 185, 243-252.
233. Morales, L.B.J.; Loo, K.K.; Liu, H.B.; Peterson, C.; Tiwari-Woodruff, S.; Voskuhl, R.R. Treatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitis. J. Neurosci., 2006, 26, 6823-6833.
234. Garidou, L.; Laffont, S.; Douin-Echinard, V.; Coureau, C.; Krust, A.; Chambon, P.; Guery, J.C. Estrogen receptor α signaling in inflammatory leukocytes is dispensable for 17β-estradiol-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol., 2004, 173, 2435-2442.
235. Tiwari-Woodruff, S.; Morales, L.B.J.; Lee, R.; Voskuhl, R.R. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)α and Erβ ligand treatment. Proc. Natl. Acad. Sci. USA, 2007, 104, 14813-14818.
236. Sicotte, N.L.; Liva, S.; Klutch, R.; Pfeiffer, P.; Bouvier, S.; Odesa, S.; Wu, T.; Voskuhl, R.R. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol., 2002, 52, 421-428.
237. Soldan, S.S.; Alvarez Retuerto, A.I.; Sicotte, N.L.; Voskuhl, R.R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol., 2003, 171, 6267-6274.
238. Vukusic, S.; Confavreux, C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin. Neurol. Neurosurg., 2006, 108, 266-270.
239. Vukusic, S.; Ionescu, I.; El-Etr, M.; Schumacher, M.; Baulieu, E.E.; Cornu, C.; Confavreux, C.; for the POPART'MUS study group. The prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J. Neurol. Sci. 2009, 286, 114-118 (see also POPARTMUS. A European multicenter trial of Post Partum Progestin and Estriol in Multiple Sclerosis. www.edmus.org/src/proj/studies_popart.html).
240. Subramanian, S.; Matejuk, A.; Zamora, A.; Vandenbark, A.A.; Offner, H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J. Immunol., 2003, 170, 1548-1555.
241. Alonso, A.; Jick, S.S.; Olek, M.J.; Ascherio, A.; Jick, H.; Hernan, M.A. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch. Neurol., 2005, 62, 1362-1365.
242. Poser, S.; Raun, N.E.; Wikstrom, J.; Poser, W. Pregnancy, oral contraceptives and multiple sclerosis. Acta Neurol. Scand, 1979, 59, 108-118.
243. Dwosh, E.; Guimond, C.; Sadovnick, A.D. Reproductive counselling in MS: a guide for healthcare professionals. Int. MS J., 2003, 10, 67.
244. Loria, R.M.; Padgett, D.A.; Huynh, P.N. Regulation of the immune response by dehydroepiandrosterone and its metabolites. J. Endocrinol., 1996, 150, S209-S220.
245. Ahlem, C.; Auci, D.; Mangano, K.; Reading, C.; Frincke, J.; Stickney, D.; Nicoletti, F. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. Ann. N.Y. Acad. Sci., 2009, 1173, 781-790.
246. Arnason, B.G.; Richman, D.P. Effect of oral contraceptives on experimental demyelinating disease. Arch. Neurol., 1969, 21, 103-108.
247. Garay, L.; Deniselle, M.C.; Lima, A.; Roig, P.; De Nicola, A.F. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J. Steroid Biochem. Mol. Biol., 2007, 107, 228-237.
248. Garay, L.; Deniselle, M.C.; Meyer, M.; Costa, J.J.; Lima, A.; Roig, P.; De Nicola, A.F. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res., 2009, 1283, 177-185.
249. Schumacher, M.; Guennoun, R.; Ghoumari, A.; Massaad, C.; Robert, F.; El-Etr, M.; Akwa, Y.; Rajkowski, K.; Baulieu, E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr. Rev., 2007, 28, 387-439.
250. Hoffman, G.E.; Le W.W.; Murphy, A.Z.; Koski, C.L. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. Exp. Neurol., 2001, 171, 272-284.
251. Arnason, B.G.; Richman, D.P. Effects of estrogen, progestin and combined estrogen progestin oral contraceptive preparations on experimental allergic encephalomyelitis. Trans. Am. Neurol. Assoc., 1969, 94, 54-58.
252. Bebo, B.F.; Schuster, J.C.; Vandenbark, A.A.; Offner, H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J. Immunol., 1999, 162, 35-40.
253. Dalal, M.; Kim, S.; Voskuhl, R.R. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen specific T lymphocyte response. J. Immunol., 1997, 59, 3-6.
254. Palaszynski, K.M.; Loo, K.K.; Ashouri, J.F.; Liu, H.B.; Voskuhl, R.R. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neuroimmunol., 2004, 146, 144-152.
255. Grinsted, L.; Heltberg, A.; Hagen, C.; Djursing, H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J. Int. Med., 1989, 226, 241-246.
256. Falaschi, P.; Martocchia, A.; Proietti, A.; D'Urso, R.; Antonini, G. High incidence of hyperandrogenism-related clinical signs in patients with multiple sclerosis. Neuroendocrinol. Lett., 2001, 22, 248-250.
257. De Andres, C.; Rodriguez-Sainz, M.C.; Munoz-Fernandez, M.A.; Lopez-Lazareno, N.; Rodriguez-Mahou M.; Vicente, A.; Fernandez-Cruz, E.; Sanchez-Ramon, S. Short-term sequential analysis of sex hormones and helper T cells type 1 (Th1) and helper T cells type 2 (Th2) cytokines during and after multiple sclerosis relapse. Eur. Cytokine Network, 2004, 15, 197-202.
258. Sicotte, N.L.; Giesser, B.S.; Tandon, V.; Klutch, R.; Steiner, B.; Drain, A.E.; Shattuck, D.W.; Hull, L.; Wang, E.J.; Elashoff, R.M.; Swerdloff, R.S.; Voskuhl, R.R. Testosterone treatment in multiple sclerosis. A pilot study. Arch. Neurol., 2007, 64, 683-688.
259. Offner, H.; Zamora, A.; Drought, H.; Matejuk, A.; Auci, D.L.; Morgan, E.E.; Vandenbark, A.A.; Reading, C.L. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing remitting EAE. J. Neuroimmunol., 2002, 130, 128-139.
260. Campbell, I.K.; Kinkel, S.A.; Drake, S.F.; van Nieuwenhuijze, A.; Hubert, F.X.; Tarlinton, D.M.; Heath, W.R.; Scott, H.S.; Wicks, I.P. Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis. Arthritis Rheum., 2009, 60, 1683-1693.
261. Khan, S.; Greenberg, J.D.; Bhardwaj, N. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat. Rev. Rheumatol., 2009, 5, 566-571.
262. Holmdahl, R.; Jansson, L.; Meyerson, B.; Klareskog, L. Oestrogen induced suppression of collagen arthritis. Long term oestradiol treatment of DBA/1 mice reduces severity and incidence of arthritis and decreases the anti type II collagen immune response. Clin. Exp. Immunol., 1987, 70, 372-378.
263. Badger, A.M.; Blake, S.M.; Dodds, R.A.; Griswold, D.E.; Swift, B.A.; Rieman, D.J.; Stroup, G.B.; Hoffman, S.J.; Gowen, M. Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis. J. Pharmacol. Exp. Ther., 1999, 291, 1380-1386.
264. Subramanian, S.; Tovey, M.; Afentoulis, M.; Krogstad, A.; Vandenbark, A.A.; Offner, H. Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β. Clin. Immunol., 2005, 115, 162-172.
265. Harris, H.A.; Albert, L.M.; Leathurby, Y.; Malamas, M.S.; Mewshaw, R.E.; Kharode, Y.P.; Marzolf, J.; Komm, B.S.: Winneker, R.C.; Frail, D.E.; Henderson, R.A.; Zhu, Y.; Keith J.C. Evaluation of an estrogen receptor-α agonist in animal models of human disease. Endocrinology, 2003, 144, 4241-4249.
266. Kuiper, S.; van Gestel, A.M.; Swinkels, H.L.; de Boo, T.M.; da Silva, J.A.; van Riel, P.L. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J. Rheumatol., 2001, 28, 1809-1816.
267. Spector, T.D.; Perry, L.A.; Tubb, G.; Silman, A.J.; Huskisson, E.C. Low free testosterone levels in rheumatoid arthritis. Ann. Rheum. Dis., 1988, 47, 65-68.
268. Ushiyama, T.; Mori, K.; Inoue, K.; Huang, J.; Nishioka, J.; Hukuda, S. Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Ann. Rheum. Dis., 1999, 58, 7-10.
269. Hall, G.M.; Daniels, M.; Huskisson, E.C.; Spector, T. D A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann. Rheum. Dis., 1994, 53, 112-116.
270. Ostensen, M.;, Forger, F.; Nelson, J.L.; Schumacher, A.; Hebisch, G.; Villiger, P.M. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis., 2005, 64, 801-803.
271. Nelson, J.L.; Ostensen, M. Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. N Am., 1997, 23 195-212.
272. Elenkov, I.J.; Wilder, R.L.; Bakalov, V.K.; Link, A.A.; Dimitrov, M.A.; Fisher, S.; Crane, M.; Kanik, K.S.; Chrousos, G.P. IL-12, TNF-α, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab., 2001, 86, 4933-4938.
273. Ostensen, M.; Sicher, P.; Forger, F.; Villiger, P.M. Activation markers of peripheral blood mononuclear cells in late pregnancy and after delivery: a pilot study. Ann. Rheum. Dis., 2005, 64, 318-320.
274. Cutolo, M.; Balleari, E.; Giusti, M.; Monachesi, M.; Accardo, S. Sex hormone status in women suffering from rheumatoid arthritis. J. Rheumatol., 1986, 13, 1019-1023.
275. Tengstrand, B.; Carlstrom, K.; Fellander-Tsai, L.; Hafstrom, I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. J. Rheumatol., 2003, 30, 2338-2343.
276. Cutolo, M.; Wilder, R.L. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum. Dis. Clin. N Am., 2000, 26, 825-839.
277. Cutolo, M.; Seriolo, B.; Villaggio, B.; Pizzorni, C.; Craviotto, C.; Sulli, A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann. N. Y. Acad. Sci., 2002, 966, 131-142.
278. Schmidt, M.; Hartung, R.; Capellino, S.; Cutolo, M.; Pfeifer-Leeg, A.; Straub, R.H. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum., 2009, 60, 2913-2922.
279. Cutolo, M.; Accardo, S.; Villaggio, B.; Clerico, P.; Indiveri, F.; Carruba, G.; Fecarotta, E.; Castagnetta, L. Evidence for the presence of androgen receptors in the synovial tissue of rheumatoid arthritis patients and healthy controls. Arthritis Rheum., 1992, 35, 1007-1015.
280. Cutolo, M.; Accardo, S.; Villaggio, B.; Clerico, P.; Bagnasco, M.; Coviello, D.A.; Carruba, G.; lo Casto, M.; Castagnetta, L. Presence of estrogen-binding sites on macrophage-like synoviocytes and CD8+, CD29+, CD45RO+, T lymphocytes in normal and rheumatoid synovium. Arthritis Rheum., 1993, 36, 1087-1097.
281. Ishizuka, M.; Hatori, M.; Suzuki, T.; Miki, Y.; Darnel, A. D; Tazawa, C.; Sawai, T.; Uzuki, M.; Tanaka, Y.; Kokubun, S.; Sasano, H. Sex steroid receptors in rheumatoid arthritis. Clin. Sci., (Lond) 2004, 106, 293-300.
282. Cutolo, M.; Accardo, S.; Villaggio, B.; Barone, A.; Sulli, A.; Balleari, E.; Bason, C.; Felli, L.; Granata, O.M.; Amodio, R.; Castagnetta, L. Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. J. Clin. Endocrinol. Metab., 1996, 81, 820-827.
283. Bijlsma, J.W.; Van den Brink, H.R. Estrogens and rheumatoid arthritis. Am. J. Reprod. Immunol., 1992, 28, 231-234.
284. Offner, H.; Firestein, G.S.; Boyle, D.L.; Pieters, R.; Frincke, J.M.; Garsd, A.; White, S.K.; Reading, C.L.; Auci, D.L. An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis J. Pharmacol. Exp. Ther., 2009, 329, 1100-1109.
285. Lassmann, H.; Bruck, W.; Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med., 2001, 7, 115-121.
286. Gerli, R.; Bistoni, O.; Russano, A.; Fiorucci, S.; Borgato, L.; Cesarotti, M.E.; Lunardi, C. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1-and Th2-type cytokine production at clonal level in different stages of disease. Clin. Exp. Immunol., 2002, 129, 549-555.
287. Ruschpler, P.; Stiehl, P. Shift in Th1 (IL-2 and IFN-α) and Th2 (IL-10 and IL-4) cytokine mRNA balance within two new histological main-types of rheumatoid-arthritis (RA). Cell. Mol. Biol., (Noisyle-grand) 2002, 48, 285-293.
288. Martocchia, A.; Frugoni, P.; Indiano, I.; Falaschi, P. A rational approach on the use of sex steroids in multiple sclerosis. Recent Pat. CNS Drug Discov., 2008, 3, 34-39.